Please assess the completion status of the following clinical trial:

Trial Title: Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient must be willing to give written Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent, make the required study visits, and follow instructions while enrolled in the study~2. Severe (factor IX activity ≤2 U/dL) hemophilia B subjects on demand therapy with a minimum of 3 bleeding episodes over the preceding 6 months or 6 bleeding episodes over the preceding 12 months; subjects on prophylaxis with a bleeding pattern as above demonstrated prior to starting prophylaxis~3. Immunocompetent (CD4 count \>400/mm3) and not receiving immune modulating or chemotherapeutic agents~4. Previously treated patients with a minimum of 150 exposure days to a factor IX preparation~5. Platelet count at least 150,000/mm3~6. Liver function: alanine transaminase \[ALT\] and aspartate transaminase \[AST\] ≤2 times the upper limit of the normal range~7. Total bilirubin ≤1.5 times the upper limit of the normal range~8. Renal function: serum creatinine ≤1.25 times the upper limit of the normal range~9. Willingness to participate in the trial for up to 12-15 months~10. European Union (EU), Israel, and Canada: Age of at least 12 years and body weight of ≥40 kilograms to participate in any PK Study or the Surgical Sub-study \[the Surgical Sub-study does not apply to the UK\]; age of at least 12 years for the prophylaxis and on demand components of the Treatment Phase and Continuation Study~    United States (US): Age of at least 12 years and body weight of ≥40 kilograms to participate in any PK Study or the Surgical Sub-study; age of at least 5 years for the prophylaxis and on demand components of the Treatment Phase and Continuation Study~11. Hemoglobin ≥7 g/dL at the time of the blood draw~Exclusion Criteria:~1. History of factor IX inhibitor ≥0.6 Bethesda units (BU)~2. Existence of another coagulation disorder~3. Evidence of thrombotic disease, fibrinolysis, or disseminated intravascular coagulation (DIC)~4. Use of an investigational drug within 30 days prior to study entry~5. On medications that could impact hemostasis, such as aspirin~6. History of poor compliance, a serious medical or social condition, or any other circumstance that, in the opinion of the investigator, would interfere with participation or compliance with the study protocol~7. History of adverse reaction to either plasma-derived factor IX or recombinant factor IX that interfered with the subject's ability to treat bleeding episodes with a factor IX product

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IB1001 (Type: EXPERIMENTAL): None
- nonacog alfa (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete